118 related articles for article (PubMed ID: 38217503)
1. Discovery of Novel Aminobutanoic Acid-Based ASCT2 Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Qin L; Cheng X; Wang S; Gong G; Su H; Huang H; Chen T; Damdinjav D; Dorjsuren B; Li Z; Qiu Z; Bian J
J Med Chem; 2024 Jan; 67(2):988-1007. PubMed ID: 38217503
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.
Hassanein M; Hight MR; Buck JR; Tantawy MN; Nickels ML; Hoeksema MD; Harris BK; Boyd K; Massion PP; Manning HC
Mol Imaging Biol; 2016 Feb; 18(1):18-23. PubMed ID: 25971659
[TBL] [Abstract][Full Text] [Related]
3. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
Wang W; Pan H; Ren F; Chen H; Ren P
Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
[TBL] [Abstract][Full Text] [Related]
4. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
5. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
6. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
7. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
8. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.
Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC
Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251
[TBL] [Abstract][Full Text] [Related]
9. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
10. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
11. The pro-proliferative effect of interferon-γ in breast cancer cell lines is dependent on stimulation of ASCT2-mediated glutamine cellular uptake.
Silva C; Andrade N; Rodrigues I; Ferreira AC; Soares ML; Martel F
Life Sci; 2021 Dec; 286():120054. PubMed ID: 34662550
[TBL] [Abstract][Full Text] [Related]
12. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer.
Ma H; Wu J; Zhou M; Wu J; Wu Z; Lin L; Huang N; Liao W; Sun L
Integr Cancer Ther; 2021; 20():15347354211045349. PubMed ID: 34590499
[TBL] [Abstract][Full Text] [Related]
14. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
15. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
16. A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth.
Wu J; Li Z; Yang Z; Guo L; Zhang Y; Deng H; Wang C; Feng M
Mol Pharm; 2018 Aug; 15(8):3032-3045. PubMed ID: 29939755
[TBL] [Abstract][Full Text] [Related]
17. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
19. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.
Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A
PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490
[TBL] [Abstract][Full Text] [Related]
20. High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes.
Gegelashvili M; Rodriguez-Kern A; Pirozhkova I; Zhang J; Sung L; Gegelashvili G
Neurochem Int; 2006; 48(6-7):611-5. PubMed ID: 16516348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
